- MedPharm has appointed Bill Humphries as Chief Executive Officer to lead its next phase of growth.
- The appointment follows MedPharm’s merger with Tergus Pharma, expanding its scientific, clinical, and commercial capabilities.
MedPharm has announced the appointment of Bill Humphries as Chief Executive Officer, positioning the company for accelerated growth following its merger with Tergus Pharma. The merger has enhanced MedPharm’s scientific expertise, clinical trial manufacturing, and commercial production capabilities in the topical and transdermal drug development sector.
Mr. Humphries brings over 36 years of leadership experience in the pharmaceutical and life sciences industries. He previously served as CEO of Alcami, leading operational improvements and revenue growth. His career includes leadership roles at Isosceles Pharmaceuticals, Ortho-Dermatologics, Merz North America, Stiefel (a GSK Company), and Allergan Pharmaceuticals. He has also held board positions at several life sciences companies, including Clearside Biomedical and Aclaris Therapeutics.
“It is a privilege to join MedPharm and the team at this important period in MedPharm’s evolution and growth aspirations,” said Humphries. “I am excited to be part of this team and leverage my direct experience in the topical and transdermal space to accelerate MedPharm’s growth.”
Pat Walsh, Chairman of the Board, expressed confidence in Humphries’ leadership, stating, “Bill’s extensive leadership experience and deep understanding of the pharmaceutical industry make him the ideal leader to guide MedPharm through its next phase of growth.”